Recombinant Human FDFT1 Protein, N-His-SUMO

Description of Recombinant Human FDFT1 Protein, N-His-SUMO

Introduction Recombinant Human FDFT1 Protein, also known as Farnesyl-Diphosphate Farnesyltransferase 1, is a key enzyme involved in the biosynthesis of cholesterol and other isoprenoids. This protein is encoded by the FDFT1 gene and is found in various tissues such as the liver, brain, and intestines. Recombinant Human FDFT1 Protein is produced using recombinant DNA technology, making it a valuable tool in various research and therapeutic applications. Structure of Recombinant Human FDFT1 Protein Recombinant Human FDFT1 Protein is a 42-kDa protein consisting of 377 amino acids. It contains two functional domains, the N-terminal domain and the C-terminal domain. The N-terminal domain is responsible for binding to the substrate, farnesyl diphosphate, while the C-terminal domain is involved in the transfer of the farnesyl group to the target protein. The crystal structure of Recombinant Human FDFT1 Protein has been determined, providing valuable insights into its mechanism of action. Activity of Recombinant Human FDFT1 Protein Recombinant Human FDFT1 Protein plays a crucial role in the mevalonate pathway, which is responsible for the biosynthesis of cholesterol and other isoprenoids. This pathway is essential for the maintenance of cellular homeostasis and the production of important molecules such as steroid hormones and bile acids. Recombinant Human FDFT1 Protein catalyzes the transfer of a farnesyl group from farnesyl diphosphate to the target protein, leading to the formation of farnesylated proteins. These farnesylated proteins play important roles in various cellular processes, including cell signaling and membrane trafficking. Application of Recombinant Human FDFT1 Protein Recombinant Human FDFT1 Protein has a wide range of applications in the fields of research and therapeutics. Some of the major applications of this protein are described below: 1. Research Recombinant Human FDFT1 Protein is a valuable tool for studying the mevalonate pathway and its role in cholesterol biosynthesis. It is also used in the development of new drugs targeting this pathway. Additionally, the crystal structure of this protein has provided valuable insights into its mechanism of action, aiding in the development of more effective inhibitors. 2. Drug Discovery The mevalonate pathway, in which Recombinant Human FDFT1 Protein plays a crucial role, has been identified as a potential target for the treatment of various diseases, including cancer and cardiovascular diseases. Recombinant Human FDFT1 Protein is used in drug discovery efforts to identify inhibitors of this pathway that could be used as potential therapeutics. 3. Therapeutics Recombinant Human FDFT1 Protein has also shown potential as a therapeutic agent itself. It has been studied as a potential target for the treatment of hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. Inhibitors of this protein have been shown to reduce cholesterol levels, making them potential candidates for the treatment of this condition. 4. Diagnostic Assays Recombinant Human FDFT1 Protein is used in diagnostic assays to detect the presence of farnesylated proteins in biological samples. These assays are important for the diagnosis of diseases such as progeria, a rare genetic disorder characterized by accelerated aging, which is caused by a mutation in the gene encoding Recombinant Human FDFT1 Protein. Conclusion In summary, Recombinant Human FDFT1 Protein is a key enzyme involved in the biosynthesis of cholesterol and other isoprenoids. Its structure, activity, and applications make it a valuable tool in various research and therapeutic fields. With ongoing research and development, this protein holds great promise for the treatment of various diseases and disorders.